EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry

Globale Muster der Polypharmazie nach Hospitalisierung wegen akuter Herzinsuffizienz: Prävalenz und Outcomes aus dem REPORT-HF-Register

Wan Ting Tay, Tiew-Hwa Katherine Teng, Wouter Ouwerkerk, John G F Cleland, Sean P Collins, Christiane E Angermann, Kenneth Dickstein, Ulf Dahlstrom, Anja Schweizer, Achim Obergfell, Kai-Hang Yiu, Mathieu Ghadanfar und 8 weitere

European Journal of Heart Failure · 01.12.2025 · 27 (12) · 2705-2715

DOI: 10.1002/ejhf.70056 ↗

Auf einen Blick

Im REPORT-HF-Register war nicht-HF-Polypharmazie nach akuter Herzinsuffizienz häufig. Höhere Medikamentenzahl war mit mehr 1-Jahres-Mortalität verbunden.

Fragestellung

Wie häufig ist nicht-HF-Polypharmazie nach akuter Herzinsuffizienz und wie ist sie mit 1-Jahres-Mortalität assoziiert?

Methode

Internationales Register REPORT-HF; Analyse von Medikation, klinischen Merkmalen und 1-Jahres-Mortalität mit multivariablen Regressionsmodellen.

Ergebnisse

18 030 Patient:innen. 39 % mit Polypharmazie, 9 % mit Hyper-Polypharmazie; mit HF-Medikation 63 % bzw. 25 %. Adjustiert war Hyper-Polypharmazie mit höherer Mortalität assoziiert: HR 1,16 (95 %-KI 1,01–1,33).

Schlussfolgerung der Autor:innen

Nicht-HF-Polypharmazie bei Herzinsuffizienz ist weltweit häufig. Die Assoziation mit weniger leitliniengerechter HF-Medikation, mehr potenziell schädlichen Medikamenten und höherer 1-Jahres-Mortalität unterstreicht die Relevanz des Themas.

Kernaussagen

  • 39 % hatten Polypharmazie, 9 % Hyper-Polypharmazie
  • Adjustiert: HR 1,16 (95 %-KI 1,01–1,33) bei Hyper-Polypharmazie
  • Weniger HF-Leitlinienmedikation, mehr potenziell schädliche Medikamente

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 01.10.2025. Verfasst von Wan Ting Tay und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Heart Centre Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Heart Failure, Polypharmacy, Registries, Hospitalization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF). While guideline-directed HF medications provide therapeutic benefits, non-HF polypharmacy, particularly involving inappropriate medications, may lead to adverse outcomes. The international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF), the largest available global acute HF registry, was used to examine the prevalence, clinical correlates, and 1-year outcome associations of non-HF polypharmacy. Methods and results Medication counts were classified as no polypharmacy (<5), polypharmacy (5–9), and hyper-polypharmacy (≥10). Potentially harmful medications were identified using the 2016 American Heart Association scientific statement. Multivariable regression models examined correlates of polypharmacy and 1-year mortality. Among 18 030 patients (66 ± 14 years, 39% women), 39% had polypharmacy and 9% had hyper-polypharmacy (63% and 25%, respectively, if including HF medications). Non-HF polypharmacy was more common in older white patients from high-income countries, with preserved ejection fraction and high comorbidity burden. Patients with greater non-HF medication use were less likely to receive guideline-directed HF medications and more likely to take medications that can worsen HF. Crude hazard ratios (HRs) for 1-year mortality were 1.16 (95% confidence interval [CI] 1.08–1.25) for polypharmacy and 1.46 (95% CI 1.31–1.63) for hyper-polypharmacy versus no polypharmacy. After adjustment, hyper-polypharmacy remained associated with increased mortality (HR 1.16, 95% CI 1.01–1.33).

Conclusions

Non-HF polypharmacy in HF is common worldwide, particularly in high-income regions. Its association with reduced use of guideline-directed HF medications and higher usage of medications causing or worsening HF, as well as elevated 1-year mortality, underscores the importance of addressing polypharmacy in HF. Clinical Trial Registration: ClinicalTrials.gov NCT02595814.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePolypharmacyRegistriesHospitalizationHumansFemaleMaleAgedPrevalenceAcute DiseaseGlobal HealthMiddle Aged

Stichwörter der Autor:innen

Harmful medicationsHeart failureHospitalizationMortalityPolypharmacy

Autor:innen und Institutionen

  • National Heart Centre Singapore, Singapore, Singapore.
  • Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Well-Being, University of Glasgow and National Heart & Lung Institute, Imperial College, London, UK.
  • Department of Emergency Medicine, Vanderbilt University Medical Center, Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville, TN, USA.
  • Comprehensive Heart Failure Center Würzburg, Department of Medicine 1, University Hospital Würzburg, Würzburg, Germany.
  • University of Bergen, Stavanger University Hospital, Stavanger, Norway.

ORCID-Profile: Carolyn S P Lam

Förderung

  • Novartis

Zitieren

APA

Tay, W. T., Teng, T. K., Ouwerkerk, W., Cleland, J. G. F., Collins, S. P., Angermann, C. E., Dickstein, K., Dahlstrom, U., Schweizer, A., Obergfell, A., Yiu, K. H., Ghadanfar, M., Hassanein, M., Ren, Q. W., Gu, W. L., Ertl, G., Perrone, S. V., Filippatos, G., Lam, C. S. P., & Tromp, J. (2025). Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry. European Journal of Heart Failure, 27(12), 2705-2715. https://doi.org/10.1002/ejhf.70056

Vancouver

Tay WT, Teng TK, Ouwerkerk W, Cleland JGF, Collins SP, Angermann CE, et al. Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry. European Journal of Heart Failure. 2025;27(12):2705-2715. doi:10.1002/ejhf.70056

BibTeX
@article{Tay2025,
  author = {Tay, Wan Ting and Teng, Tiew-Hwa Katherine and Ouwerkerk, Wouter and Cleland, John G F and Collins, Sean P and Angermann, Christiane E and Dickstein, Kenneth and Dahlstrom, Ulf and Schweizer, Anja and Obergfell, Achim and Yiu, Kai-Hang and Ghadanfar, Mathieu and Hassanein, Mahmoud and Ren, Qing-Wen and Gu, Wen-Li and Ertl, Georg and Perrone, Sergio V and Filippatos, Gerasimos and Lam, Carolyn S P and Tromp, Jasper},
  title = {Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {2705--2715},
  doi = {10.1002/ejhf.70056}
}
Kostenlos starten →